Skip to main content
main-content
Erschienen in: Der Internist 3/2008

01.03.2008 | Schwerpunkt

Hypereosinophiles Syndrom und Churg-Strauss-Syndrom

Ist die Differenzierung der Syndrome klinisch relevant?

verfasst von: PD Dr. B. Hellmich, K. Holl-Ulrich, H. Merz, W.L. Gross

Erschienen in: Die Innere Medizin | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Klinisch weisen das Churg-Strauss-Syndrom und das hypereosinophile Syndrom insbesondere in den frühen Krankheitsstadien zahlreiche Gemeinsamkeiten auf. So sind neben der bei beiden Erkrankungen obligaten Blut- und Gewebseosinophilie häufig periphere Neuropathien, Hauteffloreszenzen, eine eosinophile Alveolitis und Gastroenteritis anzutreffen. Definitionsgemäß unterscheidet sich das Churg-Strauss-Syndrom vom hypereosinophilen Syndrom durch den Nachweis einer systemischen Vaskulitis, jedoch werden nicht selten Symptome der Gewebseosinophilie als „indirekte Vaskulitiszeichen“ (fehl)interpretiert. Neue gezieltere Therapieverfahren und neue diagnostische Methoden machen eine frühzeitige Differenzierung zwischen den Syndromen zunehmend klinisch relevant. Bei Patienten mit hypereosinophilem Syndrom sollte eine Untersuchung der FIP1L1-PDGRFA-Mutation erfolgen, um Patienten zu identifizieren, die von einer kausalen Therapie mit einem Tyrosinkinasehemmer wie Imatinib profitieren. Die Therapie des Churg-Strauss-Syndroms ist derzeit (noch) primär immunsuppressiv. Neuere Therapieansätze bei beiden Erkrankungen bestehen in der Immunmodulation durch Interferon α sowie Biologika, wie z. B. Antikörpern gegen Interleukin 5.
Literatur
1.
Zurück zum Zitat Bain BJ (2003) Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol 122: 173–179 PubMedCrossRef Bain BJ (2003) Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol 122: 173–179 PubMedCrossRef
2.
Zurück zum Zitat Berki T, David M, Bone B et al. (2003) New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome and secondary herpyerosinophilic states. Pathol Oncol Res 7: 292–297 CrossRef Berki T, David M, Bone B et al. (2003) New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome and secondary herpyerosinophilic states. Pathol Oncol Res 7: 292–297 CrossRef
3.
Zurück zum Zitat Butterfield JH, Gleich GJ (1994) Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 121: 648–653 PubMed Butterfield JH, Gleich GJ (1994) Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 121: 648–653 PubMed
4.
Zurück zum Zitat Churg A, Brallas M, Cronin S, Churg J (1995) Formes frustes of Churg-Strauss syndrome. Chest 108: 320–323 PubMedCrossRef Churg A, Brallas M, Cronin S, Churg J (1995) Formes frustes of Churg-Strauss syndrome. Chest 108: 320–323 PubMedCrossRef
5.
Zurück zum Zitat Churg J, Strauss L (1951) Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 27: 272–301 Churg J, Strauss L (1951) Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 27: 272–301
6.
Zurück zum Zitat Chusid M, Dale D, West B, Wolf S (1975) The hypereosinophilic syndrome. Analysis of fourteen cases and review of the literature. Medicine (Baltimore) 54: 1–27 Chusid M, Dale D, West B, Wolf S (1975) The hypereosinophilic syndrome. Analysis of fourteen cases and review of the literature. Medicine (Baltimore) 54: 1–27
7.
Zurück zum Zitat Cohen P, Pagnoux C, Mahr A et al. (2007) Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57: 686–693 PubMedCrossRef Cohen P, Pagnoux C, Mahr A et al. (2007) Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57: 686–693 PubMedCrossRef
8.
Zurück zum Zitat Cools J, DeAngelo DJ, Gotlib J et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214 PubMedCrossRef Cools J, DeAngelo DJ, Gotlib J et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214 PubMedCrossRef
9.
Zurück zum Zitat Csernok E, Trabandt A, Muller A et al. (1999) Cytokine profiles in Wegener’s granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42: 742–750 PubMedCrossRef Csernok E, Trabandt A, Muller A et al. (1999) Cytokine profiles in Wegener’s granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42: 742–750 PubMedCrossRef
10.
Zurück zum Zitat Davis MD, Daoud MS, McEvoy MT, Su WP (1997) Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 37: 199–203 PubMedCrossRef Davis MD, Daoud MS, McEvoy MT, Su WP (1997) Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 37: 199–203 PubMedCrossRef
11.
Zurück zum Zitat Gotlib J, Cools J, Malone JM et al. (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103: 2879–2891 PubMedCrossRef Gotlib J, Cools J, Malone JM et al. (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103: 2879–2891 PubMedCrossRef
12.
Zurück zum Zitat Gotlib J, Cross NC, Gilliland DG (2006) Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 19: 535–569 PubMedCrossRef Gotlib J, Cross NC, Gilliland DG (2006) Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 19: 535–569 PubMedCrossRef
13.
Zurück zum Zitat Guillevin L, Cohen P, Gayraud M et al. (1999) Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78: 26–37 Guillevin L, Cohen P, Gayraud M et al. (1999) Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78: 26–37
14.
Zurück zum Zitat Guillevin L, Lhote F, Gayraud M et al. (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. Medicine (Baltimore) 75: 17–28 Guillevin L, Lhote F, Gayraud M et al. (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. Medicine (Baltimore) 75: 17–28
15.
Zurück zum Zitat Haferlach T, Bacher U, Kern W et al. (2007) The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 87: 1–10 PubMedCrossRef Haferlach T, Bacher U, Kern W et al. (2007) The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 87: 1–10 PubMedCrossRef
16.
Zurück zum Zitat Hattori N, Ichimura M, Nagamatus M et al. (1999) Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 122: 427–439 PubMedCrossRef Hattori N, Ichimura M, Nagamatus M et al. (1999) Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 122: 427–439 PubMedCrossRef
17.
Zurück zum Zitat Hauser T, Mahr A, Metzler C et al. (2006) Leukotriene receptor antagonists (Montelukast) and the risk of Churg-Strauss Syndrome (CSS): A case-crossover study. Arthritis Rheum (Suppl 9) 54: S496 Hauser T, Mahr A, Metzler C et al. (2006) Leukotriene receptor antagonists (Montelukast) and the risk of Churg-Strauss Syndrome (CSS): A case-crossover study. Arthritis Rheum (Suppl 9) 54: S496
18.
Zurück zum Zitat Hellmich B, Csernok E, Gross W (2005) Proinflammatory cytokines and autoimmunity in Churg Strauss syndrome. Ann N Y Acad Sci 1051: 121–131 PubMedCrossRef Hellmich B, Csernok E, Gross W (2005) Proinflammatory cytokines and autoimmunity in Churg Strauss syndrome. Ann N Y Acad Sci 1051: 121–131 PubMedCrossRef
19.
Zurück zum Zitat Hellmich B, Ehlers S, Csernok E, Gross WL (2003) Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol (Suppl 32) 21: S69–S77 Hellmich B, Ehlers S, Csernok E, Gross WL (2003) Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol (Suppl 32) 21: S69–S77
20.
Zurück zum Zitat Hellmich B, Gross W (2005) Difficult to diagnose manifestations of vasculitis: does an interdisciplinary approach help? Best Pract Res Clin Rheumatol 19: 243–261 PubMedCrossRef Hellmich B, Gross W (2005) Difficult to diagnose manifestations of vasculitis: does an interdisciplinary approach help? Best Pract Res Clin Rheumatol 19: 243–261 PubMedCrossRef
21.
Zurück zum Zitat Hellmich B, Gross WL (2003) Churg-Strauss Syndrom nach Behandlung mit Leukotrienrezeptorantagonisten: Demaskierung durch Steroidreduktion oder Nebenwirkung? Dtsch Med Wochenschr 128: 1469 PubMedCrossRef Hellmich B, Gross WL (2003) Churg-Strauss Syndrom nach Behandlung mit Leukotrienrezeptorantagonisten: Demaskierung durch Steroidreduktion oder Nebenwirkung? Dtsch Med Wochenschr 128: 1469 PubMedCrossRef
22.
Zurück zum Zitat Hellmich B, Gross WL (2004) Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 5: 25–35 PubMedCrossRef Hellmich B, Gross WL (2004) Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 5: 25–35 PubMedCrossRef
23.
Zurück zum Zitat Hellmich B, Lamprecht P, Aries P, Gross W (2005) Frühdiagnose von Vaskulitiden. Z Rheumatol 64: 538–546 PubMedCrossRef Hellmich B, Lamprecht P, Aries P, Gross W (2005) Frühdiagnose von Vaskulitiden. Z Rheumatol 64: 538–546 PubMedCrossRef
24.
Zurück zum Zitat Hellmich B, Merkel F, Weber M, Gross W (2005) Frühdiagnose von chronisch-entzündlichen Systemerkrankungen. Internist 46: 421–432 PubMedCrossRef Hellmich B, Merkel F, Weber M, Gross W (2005) Frühdiagnose von chronisch-entzündlichen Systemerkrankungen. Internist 46: 421–432 PubMedCrossRef
25.
Zurück zum Zitat Jennette J, Andrassy K, Bacon PA et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187–192 PubMedCrossRef Jennette J, Andrassy K, Bacon PA et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187–192 PubMedCrossRef
26.
Zurück zum Zitat Jennette JC, Falk RJ, Andrassy K et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187–192 PubMedCrossRef Jennette JC, Falk RJ, Andrassy K et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187–192 PubMedCrossRef
27.
Zurück zum Zitat Jovanovic JV, Score J, Waghorn K et al. (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109: 4635–4640 PubMedCrossRef Jovanovic JV, Score J, Waghorn K et al. (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109: 4635–4640 PubMedCrossRef
28.
Zurück zum Zitat Keogh KA, Specks U (2003) Churg-Strauss syndrome. Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115: 284–290 PubMedCrossRef Keogh KA, Specks U (2003) Churg-Strauss syndrome. Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115: 284–290 PubMedCrossRef
29.
Zurück zum Zitat Kiene M, Csernok E, Mueller A et al. (2001) Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 44: 469–473 PubMedCrossRef Kiene M, Csernok E, Mueller A et al. (2001) Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 44: 469–473 PubMedCrossRef
30.
Zurück zum Zitat Klion AD, Bochner BS, Gleich GJ et al. (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117: 1292–1302 PubMedCrossRef Klion AD, Bochner BS, Gleich GJ et al. (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117: 1292–1302 PubMedCrossRef
31.
Zurück zum Zitat Klion AD, Noel P, Akin C et al. (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101: 4660–4666 PubMedCrossRef Klion AD, Noel P, Akin C et al. (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101: 4660–4666 PubMedCrossRef
32.
Zurück zum Zitat Lanham J, Elkon K, Pusey C, Hughes G (1984) Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63: 65–81 Lanham J, Elkon K, Pusey C, Hughes G (1984) Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63: 65–81
33.
Zurück zum Zitat Manger B, Krapf F, Gramatzki M et al. (1985) IgE-containing circulating immune complexes in Churg-Strauss vasculitis. Scand J Rheumatol 21: 369–373 Manger B, Krapf F, Gramatzki M et al. (1985) IgE-containing circulating immune complexes in Churg-Strauss vasculitis. Scand J Rheumatol 21: 369–373
34.
Zurück zum Zitat Masi AT, Hunder GG, Lie JT et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094–1100 PubMedCrossRef Masi AT, Hunder GG, Lie JT et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094–1100 PubMedCrossRef
35.
Zurück zum Zitat Means-Markwell M, Burgess T, deKeratry D et al. (2000) Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15. N Engl J Med 342: 1568–1571 PubMedCrossRef Means-Markwell M, Burgess T, deKeratry D et al. (2000) Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15. N Engl J Med 342: 1568–1571 PubMedCrossRef
36.
Zurück zum Zitat Metzler C, Csernok E, Gross W, Hellmich B (2005) Interferon-alpha for maintenance of remission in Churg-Strauss syndrome. First results of a phase two open label prospective study. Arthritis Rheum 52: S648 Metzler C, Csernok E, Gross W, Hellmich B (2005) Interferon-alpha for maintenance of remission in Churg-Strauss syndrome. First results of a phase two open label prospective study. Arthritis Rheum 52: S648
37.
Zurück zum Zitat Metzler C, Hellmich B, Gause A et al. (2004) Churg Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22 (Suppl 36): S52–S61 PubMed Metzler C, Hellmich B, Gause A et al. (2004) Churg Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22 (Suppl 36): S52–S61 PubMed
38.
Zurück zum Zitat Mitsuyama H, Matsuyama W, Watanabe M et al. (2007) Increased expression of TRAIL receptor 3 on eosinophils in Churg-Strauss syndrome. Arthritis Rheum 56: 662–673 PubMedCrossRef Mitsuyama H, Matsuyama W, Watanabe M et al. (2007) Increased expression of TRAIL receptor 3 on eosinophils in Churg-Strauss syndrome. Arthritis Rheum 56: 662–673 PubMedCrossRef
39.
Zurück zum Zitat Muschen M, Warskulat U, Perniok A et al. (1999) Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol 155: 915–925 PubMed Muschen M, Warskulat U, Perniok A et al. (1999) Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol 155: 915–925 PubMed
40.
Zurück zum Zitat Plotz SG, Simon HU, Darsow U et al. (2003) Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349: 2334–2339 PubMedCrossRef Plotz SG, Simon HU, Darsow U et al. (2003) Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349: 2334–2339 PubMedCrossRef
41.
Zurück zum Zitat Rothenberg ME, Gleich G, Roufosse F et al. (2006) Steroid-sparing effects of anti-IL-5 monoclonal antibody (mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial. Blood 108: Abstract #373 Rothenberg ME, Gleich G, Roufosse F et al. (2006) Steroid-sparing effects of anti-IL-5 monoclonal antibody (mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial. Blood 108: Abstract #373
42.
Zurück zum Zitat Sable-Fourtassou R, Cohen P, Mahr A et al. (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143: 632–638 PubMed Sable-Fourtassou R, Cohen P, Mahr A et al. (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143: 632–638 PubMed
43.
Zurück zum Zitat Sade K, Mysels A, Levo Y, Kivity S (2007) Eosinophilia: A study of 100 hospitalized patients. Eur J Intern Med 18: 196–201 PubMedCrossRef Sade K, Mysels A, Levo Y, Kivity S (2007) Eosinophilia: A study of 100 hospitalized patients. Eur J Intern Med 18: 196–201 PubMedCrossRef
44.
Zurück zum Zitat Sharma A, De Varennes B, Sniderman AD (1993) Churg-Strauss syndrome presenting with marked eosinophilia and pericardial effusion. Can J Cardiol 9: 329–330 PubMed Sharma A, De Varennes B, Sniderman AD (1993) Churg-Strauss syndrome presenting with marked eosinophilia and pericardial effusion. Can J Cardiol 9: 329–330 PubMed
45.
Zurück zum Zitat Simon HU, Plotz SG, Dummer R, Blaser K (1999) Abnormal clones of T-cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341: 1112–1120 PubMedCrossRef Simon HU, Plotz SG, Dummer R, Blaser K (1999) Abnormal clones of T-cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341: 1112–1120 PubMedCrossRef
46.
Zurück zum Zitat Sinico RA, Di Toma L, Maggiore U et al. (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52: 2926–2935 PubMedCrossRef Sinico RA, Di Toma L, Maggiore U et al. (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52: 2926–2935 PubMedCrossRef
47.
Zurück zum Zitat Tashiro H, Shirasaki R, Noguchi M et al. (2006) Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. Int J Hematol 83: 433–438 PubMedCrossRef Tashiro H, Shirasaki R, Noguchi M et al. (2006) Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. Int J Hematol 83: 433–438 PubMedCrossRef
48.
Zurück zum Zitat Tatsis E, Schnabel A, Gross W (1998) Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129: 370–374 PubMed Tatsis E, Schnabel A, Gross W (1998) Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129: 370–374 PubMed
49.
Zurück zum Zitat Tefferi A, Vardiman JW (2007) Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 20: 20 Tefferi A, Vardiman JW (2007) Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 20: 20
50.
Zurück zum Zitat Vandenberghe P, Wlodarska I, Michaux L et al. (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18: 734–742 PubMedCrossRef Vandenberghe P, Wlodarska I, Michaux L et al. (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18: 734–742 PubMedCrossRef
51.
Zurück zum Zitat Weller P, Plaut M, Taggart V, Trontell A (2001) The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 108: 175–183 PubMedCrossRef Weller P, Plaut M, Taggart V, Trontell A (2001) The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 108: 175–183 PubMedCrossRef
52.
Zurück zum Zitat Xiao S, Nalabolu SR, Aster JC et al. (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 18: 84–87 PubMedCrossRef Xiao S, Nalabolu SR, Aster JC et al. (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 18: 84–87 PubMedCrossRef
Metadaten
Titel
Hypereosinophiles Syndrom und Churg-Strauss-Syndrom
Ist die Differenzierung der Syndrome klinisch relevant?
verfasst von
PD Dr. B. Hellmich
K. Holl-Ulrich
H. Merz
W.L. Gross
Publikationsdatum
01.03.2008
Verlag
Springer-Verlag
Erschienen in
Die Innere Medizin / Ausgabe 3/2008
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-007-2009-4

Weitere Artikel der Ausgabe 3/2008

Der Internist 3/2008 Zur Ausgabe

Mitteilungen des BDI

Mitteilungen des BDI 03/08

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.